Cemex S.A.B. de C.V. Sponsored ADR vs Cassava Sciences Inc — how do they compare? Cemex S.A.B. de C.V. Sponsored ADR trades at $9.45 (market cap $13.79B), while Cassava Sciences Inc trades at $0.83 (market cap $39.40M). The key difference: Cemex S.A.B. de C.V. Sponsored ADR is far larger — about 350× Cassava Sciences Inc's market cap, and Cemex S.A.B. de C.V. Sponsored ADR pays a 1.3% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cemex S.A.B. de C.V. Sponsored ADR for 0 Days and Cassava Sciences Inc for 37 Days on average.
| CX | FLNA | |
|---|---|---|
Market Cap | $13.79B | $39.40M |
Volume | 3,993,982 | 759,018 |
Sector | Basic Materials | Health |
52-Week High | $13.55 | $4.64 |
52-Week Low | $9.12 | $0.68 |
Typical Hold Time | 0 Days | 37 Days |
Enterprise Value | $19.79B | -$43.28M |
Dividend Yield | 1.3% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).
The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Cemex produces, distributes, markets, and sells cement, ready-mix concrete, aggregates, and other construction materials. Its operations serve markets around the world.
Read more on CX →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →